
|Articles|June 22, 2016
Pembrolizumab Yields Strong Long-Term Survival in Advanced Melanoma
Author(s)Caroline Robert, MD, PhD
In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.
Advertisement
Long-term results of the KEYNOTE-001 trial found that 40% of patients with advanced melanoma treated with the anti–PD-1 antibody pembrolizumab were alive at 3 years, according to data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract
In this video, Caroline Robert, MD, PhD, of the Institut Gustave Roussy in Paris, discusses these new results.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis
5























































